ライフサイエンスコーパス: cryptogenic

1 entifiable risk factors and are labelled as "cryptogenic".

2 primary sclerosing cholangitis, ethanol, and cryptogenic.

3 c (e.g., primary biliary cirrhosis), and (3) cryptogenic.

4 nd the largest subtype within this cohort is cryptogenic.

5 n certain patients whose stroke is otherwise cryptogenic.

6 henotype models were applied to cases deemed cryptogenic.

7 ied, and they are often termed idiopathic or cryptogenic.

8 .9%), ALD 0.7% (0.5-0.9%), etiology-specific/cryptogenic 0.03% (0.01%-0.08%).

9 minor-risk echocardiographic abnormalities (cryptogenic 37% vs 45%; p=0.18) or paroxysmal AF (6% vs

10 ould be part of our diagnostic algorithm of "cryptogenic abscesses" since surgical removal of the for

11 d aplastic anemia, and 0 of 17 patients with cryptogenic acute liver failure, compared with 150 (24%)

12 c cortex studied in postsurgical tissue from cryptogenic and FCD patients.

13 e likely susceptibility genes for developing cryptogenic and noncryptogenic forms of liver disease.

14 conditions such as aneurysmal SAH (aSAH) or cryptogenic "angiogram-negative" SAH (cSAH) owing to ove

15 us indications, 44 patients transplanted for cryptogenic, autoimmune, hepatitis B, or cholestatic liv

16 The proportion of cryptogenic cases will decrease with improvements in MRI

17 igin of pneumatosis intestinalis will remain cryptogenic--caused but unexplained.

18 ctive observational studies of patients with cryptogenic cerebral ischemia that provided both sensiti

19 an be detected in up to 43% of patients with cryptogenic cerebral ischemia undergoing investigation w

20 TE for the detection of PFO in patients with cryptogenic cerebral ischemia.

21 Fibrosis scores for cryptogenic, cholestatic, and alcoholic recipients were

22 Autoimmune hepatitis (AIH) and cryptogenic chronic hepatitis (CCH) are important causes

23 Cryptogenic chronic hepatitis is indistinguishable from

24 a diagnosis of AIH to 20 of 21 patients with cryptogenic chronic hepatitis, whereas only five patient

25 rticosteroids can also benefit patients with cryptogenic chronic hepatitis.

26 syndromes include autoimmune cholangitis and cryptogenic chronic hepatitis.

27 included: hepatitis C (24), hepatitis B (9), cryptogenic cirrhosis (1), hemochromatosis (1), and prim

28 n aetiology was alcohol (50.5%), followed by cryptogenic cirrhosis (14.5%), hepatitis C (13.4%), and

29 , 37 of 187 with ALD (20%), and 9 of 39 with cryptogenic cirrhosis (23.1%) were identified as PI MZ,

30 y of liver disease was hepatitis C (51%) and cryptogenic cirrhosis (29%).

31 nt survival of NASH (n = 7935) patients with cryptogenic cirrhosis (CC) (n = 6087), alcoholic cirrhos

32 titis (NASH) is an under-recognized cause of cryptogenic cirrhosis (CC) on the basis of higher preval

33 er disease (n=495), alcohol and HCV (n=152), cryptogenic cirrhosis (CC, n=289), nonalcoholic steatohe

34 =8940), HCV+alcohol (n=6066), NASH (n=1368), cryptogenic cirrhosis (CC; n=5856), hepatitis B virus (H

35 red them with groups that received re-LT for cryptogenic cirrhosis (n = 189), alcoholic cirrhosis (n

36 he primary diagnosis was hepatitis C (n=16), cryptogenic cirrhosis (n=2), and autoimmune hepatitis (n

37 s (HCV) (n=2), HCV (n=1), alcohol (n=1), and cryptogenic cirrhosis (n=3).

38 al Parenteral Nutrition (TPN)-related (one), cryptogenic cirrhosis (one), and hepatoblastoma (one).

39 tio [OR], 3.2; 95% CI, 1.5-6.6; P =.002) and cryptogenic cirrhosis (OR, 11.1; 95% CI, 1.5-87.4; P =.0

40 n hepatitis C virus (HCV) liver (P <.05) and cryptogenic cirrhosis (P <.01) compared with normal cont

41 proportion of women, a greater prevalence of cryptogenic cirrhosis (P <.05) and diabetes (P <.05), an

42 ipients (2003-2012) transplanted for NASH or cryptogenic cirrhosis (the NASH cohort) without pre-tran

43 on in patients with liver disease, including cryptogenic cirrhosis and fulminant hepatic failure.

44 frequencies after liver transplantation for cryptogenic cirrhosis and hepatitis C (HCV).

45 with liver disease, including patients with cryptogenic cirrhosis and idiopathic fulminant hepatic f

46 gher incidence of liver disease secondary to cryptogenic cirrhosis and Laennec's cirrhosis.

47 idence to HGV infection not being a cause of cryptogenic cirrhosis and not being associated with the

48 rify the role of HGV as a causative agent in cryptogenic cirrhosis by analyzing archival liver tissue

49 r of PI MZ carriers existed in patients with cryptogenic cirrhosis compared with other liver disease

50 Half of the patients with cryptogenic cirrhosis had histologic or clinical feature

51 ns in K18 may be predispose to, or result in cryptogenic cirrhosis in humans.

52 Cryptogenic cirrhosis is a common cause of liver-related

53 HGV infection in patients undergoing OLT for cryptogenic cirrhosis is about 25%.

54 n recipients who undergo transplantation for cryptogenic cirrhosis is similar to that of recipients w

55 t HGV-RNA within the livers of patients with cryptogenic cirrhosis or in the HCC arising within them.

56 he diagnoses of primary biliary cirrhosis or cryptogenic cirrhosis than younger recipients, who were

57 ->leu (H127L) K18 mutation in a patient with cryptogenic cirrhosis that is germline transmitted.

58 s, and Mallory hyaline, and two patients had cryptogenic cirrhosis thought to represent "burned out"

59 HGV infection in recipients transplanted for cryptogenic cirrhosis was 26%.

60 Patients with cryptogenic cirrhosis were less likely to have undergone

61 on were studied: 50 were diagnosed as having cryptogenic cirrhosis while 39 had nonviral chronic live

62 or alcoholic cirrhosis (group I), NASH, and cryptogenic cirrhosis with body mass index greater than

63 blood donors, 15% (5 of 33) of patients with cryptogenic cirrhosis, 27% (3 of 11) of patients with id

64 itis, 6 with alcoholic liver disease, 4 with cryptogenic cirrhosis, 4 with biliary atresia, and 10 no

65 ur groups of recipients: 31 transplanted for cryptogenic cirrhosis, 70 for cholestatic etiologies, 40

66 ic cirrhosis, 52.6%; viral cirrhosis, 21.8%; cryptogenic cirrhosis, 8.4%; autoimmune cirrhosis, 5.8%;

67 ients with a pretransplantation diagnosis of cryptogenic cirrhosis, although the disease was generall

68 ion in the keratin 18 gene in a patient with cryptogenic cirrhosis, but the importance of mutations i

69 (K8K18) mutations are found in patients with cryptogenic cirrhosis, but the role of keratin mutations

70 Cryptogenic cirrhosis, hypertension, and coronary artery

71 Blood donors, patients with cryptogenic cirrhosis, idiopathic fulminant hepatic fail

72 isease for which no cause can be identified, cryptogenic cirrhosis, is a common indication for liver

73 AFLD was also defined by clinical diagnosis (cryptogenic cirrhosis, obese-diabetics with cryptogenic

74 unts for a large proportion of idiopathic or cryptogenic cirrhosis, which is associated with the typi

75 those with NASH, and NASH may be a cause of cryptogenic cirrhosis.

76 s now recognized as the most common cause of cryptogenic cirrhosis.

77 rranted in obese patients with alcoholic and cryptogenic cirrhosis.

78 s is confined to alcoholic liver disease and cryptogenic cirrhosis.

79 -M4 developed 19 months after transplant for cryptogenic cirrhosis.

80 e generally stable after transplantation for cryptogenic cirrhosis.

81 ver disease in the majority of patients with cryptogenic cirrhosis.

82 rrhosis, primary sclerosing cholangitis, and cryptogenic cirrhosis.

83 ng associated with the development of HCC in cryptogenic cirrhosis.

84 derwent orthotopic liver transplantation for cryptogenic cirrhosis.

85 ents infected with HGV who underwent OLT for cryptogenic cirrhosis.

86 tation (mean age, 50 years; M:F, 18:28) with cryptogenic cirrhosis.

87 One patient was diagnosed as cryptogenic cirrhosis.

88 was significantly enriched in NASH, ALD, and cryptogenic cirrhosis.

89 patitis (NASH), hereditary dyslipidaemia, or cryptogenic cirrhosis.

90 ations previously described in patients with cryptogenic cirrhosis: K8 Tyr-53 --> His, K8 Gly-61 -->

91 The diagnostic yield across cryptogenic CP cohorts was 35% (95% CI, 27%-45%), compar

92 e cases, CP is evident without risk factors (cryptogenic CP).

93 a-analysis suggest that for individuals with cryptogenic CP, ES followed by CMA to identify molecular

94 guish CS from SO and identify IS etiology in cryptogenic CS patients.

95 antly in participants who had idiopathic and cryptogenic CSE (seven [36.8%, 95% CI 19.1-59.0] and 16

96 f subsequent epilepsy is not increased after cryptogenic CSE.

97 1% women) who underwent PFO closure due to a cryptogenic embolism (stroke: 76%, transient ischemic at

98 nt foramen ovale for secondary prevention of cryptogenic embolism did not result in a significant red

99 The options for secondary prevention of cryptogenic embolism in patients with patent foramen ova

100 c epilepsy had increased risk for idiopathic/cryptogenic epilepsy and for epilepsy associated with ne

101 psy in relatives of probands with idiopathic/cryptogenic epilepsy diminished with increasing age of t

102 Relatives of probands with idiopathic/cryptogenic epilepsy had increased risk for idiopathic/c

103 d POINTER to perform segregation analysis of cryptogenic epilepsy in 1,557 three-generation families

104 The degree of increased risk of idiopathic/cryptogenic epilepsy in relatives of probands with idiop

105 ts suggest that the familial distribution of cryptogenic epilepsy is inconsistent with any convention

106 Prevalence of idiopathic/cryptogenic epilepsy was only 3.7% in newly identified r

107 rs for people with a diagnosis of idiopathic/cryptogenic epilepsy, and the reduction can be up to 10

108 odeficits had increased risks for idiopathic/cryptogenic epilepsy.

109 pathology can be seen in many patients with "cryptogenic" epilepsy.

110 % CI, 2.6-21.5), especially in patients with cryptogenic events (10 [18.5%] vs 63 [49.2%]; absolute d

111 Among 2555 patients, 812 (32%) had cryptogenic events (incidence of cryptogenic stroke 0.36

112 mall vessel subtypes combined, patients with cryptogenic events also had no excess of minor-risk echo

113 atients with large artery events, those with cryptogenic events had less hypertension (adjusted odds

114 ce rates are comparable with other subtypes, cryptogenic events have the fewest atherosclerotic marke

115 pril 1, 2002, to March 31, 2014, we compared cryptogenic events versus other causative subtypes accor

116 The majority of cryptogenic FHF cases cannot be attributed to infection

117 was to evaluate interstitial vascularity in cryptogenic fibrosing alveolitis (CFA) and in fibrosing

118 Lone cryptogenic fibrosing alveolitis (CFA) is a progressive

119 We have previously suggested that cryptogenic fibrosing alveolitis (CFA) may be caused by

120 r was markedly increased among patients with cryptogenic fibrosing alveolitis (rate ratio [RR] 7.31,

121 sed cohort study involving 890 subjects with cryptogenic fibrosing alveolitis and 5, 884 control subj

122 t cigarette smoking may be a risk factor for cryptogenic fibrosing alveolitis as well as for lung can

123 se in lung cancer incidence in patients with cryptogenic fibrosing alveolitis compared with the gener

124 Cryptogenic fibrosing alveolitis has been reported to be

125 of lung cancer is increased in patients with cryptogenic fibrosing alveolitis, and that this effect i

126 ted the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF).

127 the hepatitis G virus (HGV) in patients with cryptogenic fulminant hepatitis (non-A-E FH).

128 However, the cryptogenic group had fewer atherosclerotic risk factors

129 profiles can predict stroke etiology in the cryptogenic group.

130 No etiological role for SENV in the cause of cryptogenic hepatitis could be demonstrated.

131 diseases, viral hepatitis and autoimmunity, cryptogenic hepatitis, and overlap syndromes.

132 est possible candidate virus associated with cryptogenic hepatitis.

133 osteopenia/osteoporosis (52%), anemia (34%), cryptogenic hypertransaminasemia (29%) and recurrent mis

134 The cause of stroke remains unknown or cryptogenic in many patients.

135 s with known biliary tract disease, is often cryptogenic in origin (ie, no clear causal factor can be

136 Pyogenic liver abscess is most often cryptogenic in origin, although sophisticated advanced i

137 atients with NORSE (n = 61, including n = 51 cryptogenic), including its subtype with prior fever kno

138 mall-vessel or lacunar infarcts, 576 had had cryptogenic infarcts, and 259 had had infarcts designate

139 cancer-associated stroke, particularly when cryptogenic, is associated with high rates of recurrent

140 The underlying risk factors for young-onset cryptogenic ischaemic stroke (CIS) remain unclear.

141 f ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown.

142 We evaluated consecutive patients with cryptogenic ischemic stroke or TIA admitted in a compreh

143 out known atrial fibrillation, who had had a cryptogenic ischemic stroke or TIA within the previous 6

144 ction and anticoagulation initiation after a cryptogenic ischemic stroke or TIA.

145 the prevention of stroke recurrence after a cryptogenic ischemic stroke or transient ischemic attack

146 TE) in the detection of PFO in patients with cryptogenic ischemic stroke or transient ischemic attack

147 d a patent foramen ovale (PFO) and had had a cryptogenic ischemic stroke to undergo closure of the PF

148 Among adults who had had a cryptogenic ischemic stroke, closure of a PFO was associ

149 medical therapy for secondary prevention of cryptogenic ischemic stroke.

150 patent foramen ovale in adults who had had a cryptogenic ischemic stroke.

151 a diabetic patient who had three episodes of cryptogenic liver abscess due to Klebsiella pneumoniae.

152 The clustering of cryptogenic liver cirrhosis with IPF suggests that the t

153 d a cluster of individuals (3%) with IPF and cryptogenic liver cirrhosis, another feature of a telome

154 pulmonary fibrosis, bone marrow failure, and cryptogenic liver cirrhosis.

155 irrhosis and dilated cardiomyopathy; one had cryptogenic liver disease and idiopathic cardiomyopathy.

156 In conclusion, hepatitis C and cryptogenic liver disease are the most common etiologies

157 people to liver disease and may account for cryptogenic liver disease in some patients.

158 (cryptogenic cirrhosis, obese-diabetics with cryptogenic liver disease).

159 Of the 55 patients with cryptogenic liver disease, 3 had glycine-to-cysteine mut

160 ts without PVT at listing included: fatty or cryptogenic liver disease, ascites, diabetes mellitus, a

161 ients who undergo liver transplantation have cryptogenic liver disease.

162 er but higher CCI in patients with fatty and cryptogenic liver disease.

163 m three groups of patients: 55 patients with cryptogenic liver disease; 98 patients with noncryptogen

164 Cryptogenic new-onset refractory status epilepticus (cNO

165 without SE, and between the 51 patients with cryptogenic NORSE (cNORSE) and the 47 patients with a kn

166 Cryptogenic (of unknown cause) ischaemic strokes are now

167 grade 3), capillary leak syndrome (grade 3), cryptogenic organising pneumonia (grade 3) and haemophag

168 l (n = 4), and bacterial (n = 5) pneumonias; cryptogenic organizing pneumonia ([COP] n = 4); and pulm

169 Various radiologic patterns of cryptogenic organizing pneumonia (COP) in X-rays have be

170 sociated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), acute interstiti

171 olitis-associated interstitial lung disease, cryptogenic organizing pneumonia (idiopathic bronchiolit

172 ticipants upon cross-validation; 11 of 16 CS-cryptogenic participants were predicted cardioembolic.

173 We also analyzed surgical specimens from cryptogenic patients not presenting structural alteratio

174 tically significant association of JPDD with cryptogenic PLA could not be established possibly becaus

175 hat offering CRC screening for patients with cryptogenic PLA may be useful, especially patients who h

176 JPDD had no other traditional risk factors (cryptogenic PLA).

177 aemic strokes are of undetermined cause (ie, cryptogenic), potentially undermining secondary preventi

178 frequency of HAI > or = 2 was more than for cryptogenic recipients at 1 year (52 vs. 29%, P=0.04) an

179 with fibrosis stage >2 was more than that of cryptogenic recipients at 4 months (29 vs. 12%, P=0.05),

180 None of the cryptogenic recipients developed cirrhosis.

181 In 4 of the 11 cryptogenic recipients in whom HGV RNA was detectable in

182 The prevalence of HAI > or = 2 among cryptogenic recipients was similar to that of cholestati

183 Of the five cryptogenic recipients who continue to have measurable H

184 in 60% (3 of 5) of persistently HGV-infected cryptogenic recipients.

185 immunological therapy is sometimes given in cryptogenic refractory status epilepticus.

186 gher in patients with cNORSE compared to non-cryptogenic RSE.

187 Cryptogenic sensory peripheral neuropathy (CSPN) is high

188 Cryptogenic sensory polyneuropathy (CSPN) is a common ge

189 d cell count, many patients can present with cryptogenic shock (shock without hypotension) with more

190 limited: just four marine non-native and one cryptogenic species that were likely introduced anthropo

191 ct of invasive species are frustrated by the cryptogenic status of a large proportion of those specie

192 = 0.025, log-rank test) and in patients with cryptogenic stroke (10.92 vs 1.82 per 100 patient-years;

193 I, 10.6%-34.7%) and lowest for patients with cryptogenic stroke (5.8%; 95% CI, 3.0%-8.5%).

194 and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, a multicenter, rando

195 atent foramen ovale (PFO) is associated with cryptogenic stroke (CS), although the pathogenicity of a

196 onstenosing carotid artery plaques (CAPs) in cryptogenic stroke (CS).

197 = 3.58, 95% CI = 1.43-8.92, I(2) = 43%) and cryptogenic stroke (OR = 3.98, 95% CI = 1.62-9.77, I(2)

198 s, LSSP was associated with a higher risk of cryptogenic stroke (OR: 1.67; 95% CI: 1.22-2.29; p < 0.0

199 ed to lower risk of stroke recurrence in our cryptogenic stroke / TIA cohort.

200 2 (32%) had cryptogenic events (incidence of cryptogenic stroke 0.36 per 1000 population per year, 95

201 Cryptogenic stroke accounts for 30% to 40% of ischemic s

202 Of these, 265 patients experienced cryptogenic stroke and 365 experienced known stroke subt

203 sis of data from 1015 patients with a recent cryptogenic stroke and biomarker evidence of atrial card

204 We investigated whether patients with cryptogenic stroke and echocardiographic features repres

205 In patients with cryptogenic stroke and evidence of atrial cardiopathy wi

206 zed clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, d

207 mpared the presence of LSSP in subjects with cryptogenic stroke and non-stroke controls was performed

208 mong 196 patients enrolled, 104 patients had cryptogenic stroke and nonstenosing CAP.

209 at can help identify potential mechanisms in cryptogenic stroke and patients who may be targeted for

210 potentiator of stroke risk in patients with cryptogenic stroke and PFO is a concomitant atrial septa

211 early 30,000 young patients each year have a cryptogenic stroke and PFO.

212 the gold standard for treating patients with cryptogenic stroke and PFO.

213 Cryptogenic Stroke and Underlying Atrial Fibrillation (C

214 The terms ESUS and cryptogenic stroke are not synonyms, as the latter also

215 Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated

216 Applying these models to cryptogenic stroke cases yielded that 51.5% fit the vasc

217 or dependency at 6 months was similar after cryptogenic stroke compared with non-cardioembolic strok

218 However, the definition of cryptogenic stroke did not meet the operational criteria

219 In our cohort, half of young patients with cryptogenic stroke fit the risk factor phenotype of smal

220 Detection of atrial fibrillation after cryptogenic stroke has therapeutic implications.

221 sed risk of ischemic stroke, and potentially cryptogenic stroke in particular.

222 alysis showed that there is a higher risk of cryptogenic stroke in patients with LSSP than in patient

223 Modern management strategies for cryptogenic stroke include long-term cardiac monitoring,

224 of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general po

225 n used for cardiac disorders, but its use in cryptogenic stroke is not well established.

226 e precise role of PFO in the pathogenesis of cryptogenic stroke is not yet established.

227 in the prevention of recurrent stroke after cryptogenic stroke is uncertain.

228 cal therapy versus medical therapy alone for cryptogenic stroke is uncertain.

229 t ischemic stroke in patients who have had a cryptogenic stroke is unknown.

230 revention of stroke in patients experiencing cryptogenic stroke or ESUS, despite several clinical tri

231 y of various MRI techniques in patients with cryptogenic stroke or ESUS.

232 In patients with cryptogenic stroke or TIA who had a patent foramen ovale

233 Among patients with a recent cryptogenic stroke or TIA who were 55 years of age or ol

234 18 and 60 years of age who presented with a cryptogenic stroke or transient ischemic attack (TIA) an

235 hing incidental PFOs from pathogenic ones in cryptogenic stroke patients and for identifying patients

236 Three-year monitoring by ICM in cryptogenic stroke patients demonstrated a significantly

237 mized study to report the detection of AF in cryptogenic stroke patients using continuous long-term m

238 The pooled prevalence of LSSP among cryptogenic stroke patients was 31.6% (95% CI: 20.6-43.8

239 The risk was highest among cryptogenic stroke patients, both for large plaques (HR,

240 pulation is around 25%, but it is doubled in cryptogenic stroke patients.

241 rences in stroke prevention strategies among cryptogenic stroke patients.

242 Cryptogenic stroke refers to a stroke of undetermined et

243 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophage

244 pirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-

245 The PFO in Cryptogenic Stroke Study was a 42-center study that eval

246 e more prevalent among patients experiencing cryptogenic stroke than among those with strokes of know

247 n the diagnostic evaluation of patients with cryptogenic stroke to identify potential aetiologies suc

248 between the LSSP presence and occurrence of cryptogenic stroke using meta-analytical methodologies.

249 schemic stroke after routine PFO closure for cryptogenic stroke was comparable to that observed in cl

250 The cause of cryptogenic stroke was predicted based on a model develo

251 Patients with prior cryptogenic stroke were randomized to control (n=220) or

252 (mean age, 49.3 years) with PFO-attributable cryptogenic stroke who were undergoing percutaneous PFO

253 th an embolic stroke of undetermined source (cryptogenic stroke) have a PFO, compared with 25% of the

254 is suspected (as in patients presenting with cryptogenic stroke) or when an ECG diagnosis of unexplai

255 F in at-risk populations (such as those with cryptogenic stroke), the refinement of AF and stroke pre

256 diagnostic evaluation in 20 to 40% of cases (cryptogenic stroke).

257 When applied to patients with cryptogenic stroke, 17% are predicted to be large-vessel

258 AF management, <8 days and suspected AF and cryptogenic stroke, 8-21 days).

259 Among patients with PFO and cryptogenic stroke, closure reduced recurrent stroke and

260 re several possible mechanisms implicated in cryptogenic stroke, including occult paroxysmal atrial f

261 In patients with stroke, especially cryptogenic stroke, large aortic plaques remain associat

262 Cryptogenic stroke, named embolic stroke of undetermined

263 proposed stroke mechanism that may underlie cryptogenic stroke, particularly in younger patients wit

264 Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stro

265 ients, closure of patent foramen ovale after cryptogenic stroke, treatment of insulin resistance, and

266 involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a

267 ggests a causal relationship between PFO and cryptogenic stroke.

268 n attempt to quantitate PFO in patients with cryptogenic stroke.

269 s essential to determine the pathogenesis in cryptogenic stroke.

270 cardiography in the diagnostic evaluation of cryptogenic stroke.

271 ed risk of recurrent events in patients with cryptogenic stroke.

272 n patients with pacemakers and patients with cryptogenic stroke.

273 botic strategies in patients with cancer and cryptogenic stroke.

274 stroke in patients 60 years or younger with cryptogenic stroke.

275 elected patients younger than 60 years after cryptogenic stroke.

276 "possible," or "unlikely" cause of otherwise cryptogenic stroke.

277 troke prevention strategies in patients with cryptogenic stroke.

278 tory comparative studies, and case series on cryptogenic stroke.

279 sure versus medical therapy in patients with cryptogenic stroke.

280 (AF) can be a cause of previously diagnosed cryptogenic stroke.

281 hophysiology have prompted a reassessment of cryptogenic stroke.

282 w-up for detecting atrial fibrillation after cryptogenic stroke.

283 tecting atrial fibrillation in patients with cryptogenic stroke.

284 may represent an opportunity for those with cryptogenic stroke.

285 Stroke of undetermined aetiology or 'cryptogenic' stroke accounts for 30-40% of ischaemic str

286 There is persuasive evidence that most cryptogenic strokes are thromboembolic.

287 is increasingly accepted that many of these cryptogenic strokes arise from a distant embolism rather

288 Cryptogenic strokes constitute approximately 40% of isch

289 rs to a subgroup of patients with nonlacunar cryptogenic strokes in whom embolism is the suspected st

290 n and have been linked to up to one-third of cryptogenic strokes in younger patients.

291 Of the cryptogenic strokes predicted to be cardioembolic, 27% w

292 RATIONALE: Cryptogenic strokes, those of unknown cause, have been e

293 vale may prevent a substantial proportion of cryptogenic strokes.

294 kes with unclear aetiology are classified as cryptogenic strokes.

295 ar event rates 14.8% versus 15.4%) or in the cryptogenic subset (P=0.65; hazard ratio 1.17; 95% CI 0.

296 The clinical burden of cryptogenic TIA and stroke is substantial.

297 me, risk factors, and long-term prognosis of cryptogenic TIA and stroke.

298 Cryptogenic was the primary etiology (70%) and the media

299 iated liver disease (ALD), etiology-specific/cryptogenic] were defined according to consensus nomencl

300 ischemic strokes (IS) in cancer patients are cryptogenic, with many presumed cardioembolic.